Articles
Vol. 1 No. 1 (2009)
https://doi.org/10.4081/jsas.2009.329

PERSISTENCE OF PH+/CD34+ CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN PROLONGED COMPLETE CYTOGENETIC REMISSION FOLLOWING IMATINIB MESYLATE TREATMENT

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 10 January 2012
Accepted: 10 January 2012
Published: 10 January 2012
1049
Views
1363
Downloads

Authors

M. Defina
info@pagepres.org
Ematology and Transplant Unit, Dept. of Clinical Medicine and Immunological Sciences, University of Siena, Italy.
M. Bocchia
Ematology and Transplant Unit, Dept. of Clinical Medicine and Immunological Sciences, University of Siena, Italy.
I. Ippoliti
Ematology and Transplant Unit, Dept. of Clinical Medicine and Immunological Sciences, University of Siena, Italy.
A. Gozzetti
Ematology and Transplant Unit, Dept. of Clinical Medicine and Immunological Sciences, University of Siena, Italy.
S. Calabrese
Ematology and Transplant Unit, Dept. of Clinical Medicine and Immunological Sciences, University of Siena, Italy.
R. Crupi
Ematology and Transplant Unit, Dept. of Clinical Medicine and Immunological Sciences, University of Siena, Italy.
I. Chitarrelli
Ematology and Transplant Unit, Dept. of Clinical Medicine and Immunological Sciences, University of Siena, Italy.
F. Lauria
info@pagepres.org, Italy.
Chronic myelogenous leukemia (CML) is characterized by a clonal expansion of a hematopoietic stem cell possessing a reciprocal translocation between chromosomes 9 and 22, the Philadelphia chromosome, as identified cytogenetically or molecularly (RT-PCR). CML accounts for 15% of adult leukemias. The disease progresses from a chronic phase through an accelerated phase to a blast phase. In the past, the National Comprehensive Cancer Network had suggested that there were three primary treatments available for CML which included: allogeneic bone marrow transplantation (BMT), IFN-α with or without cytarabine, and imatinib mesylate (Glivec®). It has been shown that Glivec is superior to the combination of interferon plus cytarabine. Although BMT can be a curative treatment for CML it is not usually used as a front-line therapy, due to limited donor availability and high toxicity of the procedure. Five-year survival rates following HLA-matched transplants are approximately 75% for patients in chronic phase.

Downloads

Download data is not yet available.

How to Cite



PERSISTENCE OF PH+/CD34+ CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN PROLONGED COMPLETE CYTOGENETIC REMISSION FOLLOWING IMATINIB MESYLATE TREATMENT. (2012). Journal of the Siena Academy of Sciences, 1(1), 15-17. https://doi.org/10.4081/jsas.2009.329

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.